CpG-matured DCs cultured in GM-CSF/IL-4 provide superior protection against murine AML challenge compared with LPS-matured DCs.
DCs were cultured and matured with either LPS or CpG 2006 and pulsed with AML (C1498) cell lysate for 18 hours then administered intravenously (0.5 × 106 cells/mouse) 14 and 7 days prior to tumor challenge with 2 × 106 C1498 cells/mouse. The mice receiving DC vaccination had significantly improved survival compared with nonvaccinated controls (P ≤ .0001). The survival advantage provided by DCs matured with CpG was significantly improved compared with the survival of mice administered GM-CSF/IL-4/LPS–matured DCs (20% versus 13% survival, respectively,P = .02). The MST of mice that received CpG-matured DCs was longer than mice that received LPS-matured DCs (73.9 versus 49.98 days, respectively). Data are pooled results of 2 independent experiments (15 total mice/group).
